The treatment of gastroesophageal reflux disease (GERD) and stomach and intestinal ulcers has piqued the interest of healthcare professionals, owing to the growing prevalence of these conditions. GERD is a frequent health issue that can result in major medical consequences as well as a significant financial outlay for diagnosis and treatment. Heartburn and acid regurgitation are the two most commonly observed symptoms of GERD. To reduce the effects of stomach acids or to stop acid production, over-the-counter antacids, proton pump inhibitors, and H-2 receptor blockers are commonly utilised.
Ranitidine is a histamine H2 antagonist that is used to treat gastroesophageal reflux disease. It is available as an over-the-counter (OTC) and prescription medicine (GERD). For up to 12 hours, ranitidine reduces stomach acid production. Erosive esophagitis, peptide ulcer disease, and Zollinger–Ellison syndrome are all treated with ranitidine. It can be administered either orally or intravenously.
Read More:
https://bloggerstrive.blogspot.com/2022/03/ranitidine-market-analysis-and-growing.html
Click here for Ranitidine Market Report:
https://www.coherentmarketinsights.com/market-insight/ranitidine-market-2131
Click here for Ranitidine Market Press Release:
Comments
0 comment